Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
J Gerontol A Biol Sci Med Sci ; 76(10): 1775-1783, 2021 09 13.
Article in English | MEDLINE | ID: covidwho-1358442


Aging and comorbidities make individuals at greatest risk of COVID-19 serious illness and mortality due to senescence-related events and deleterious inflammation. Long-living individuals (LLIs) are less susceptible to inflammation and develop more resiliency to COVID-19. As demonstrated, LLIs are characterized by high circulating levels of BPIFB4, a protein involved in homeostatic response to inflammatory stimuli. Also, LLIs show enrichment of homozygous genotype for the minor alleles of a 4 missense single-nucleotide polymorphism haplotype (longevity-associated variant [LAV]) in BPIFB4, able to counteract progression of diseases in animal models. Thus, the present study was designed to assess the presence and significance of BPIFB4 level in COVID-19 patients and the potential therapeutic use of LAV-BPIFB4 in fighting COVID-19. BPIFB4 plasma concentration was found significantly higher in LLIs compared to old healthy controls while it significantly decreased in 64 COVID-19 patients. Further, the drop in BPIFB4 values correlated with disease severity. Accordingly to the LAV-BPIFB4 immunomodulatory role, while lysates of SARS-CoV-2-infected cells induced an inflammatory response in healthy peripheral blood mononuclear cells in vitro, the co-treatment with recombinant protein (rh) LAV-BPIFB4 resulted in a protective and self-limiting reaction, culminating in the downregulation of CD69 activating-marker for T cells (both TCD4+ and TCD8+) and in MCP-1 reduction. On the contrary, rhLAV-BPIFB4 induced a rapid increase in IL-18 and IL-1b levels, shown largely protective during the early stages of the virus infection. This evidence, along with the ability of rhLAV-BPIFB4 to counteract the cytotoxicity induced by SARS-CoV-2 lysate in selected target cell lines, corroborates BPIFB4 prognostic value and open new therapeutic possibilities in more vulnerable people.

COVID-19 , Intercellular Signaling Peptides and Proteins , Longevity/immunology , Aged, 80 and over , Biomarkers/blood , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/immunology , Cell Line , Cytokines/blood , Cytotoxicity, Immunologic/drug effects , Female , Humans , Immunologic Factors/immunology , Immunologic Factors/pharmacology , Inflammation/blood , Inflammation/immunology , Intercellular Signaling Peptides and Proteins/blood , Intercellular Signaling Peptides and Proteins/immunology , Italy/epidemiology , Male , Prognosis , Recombinant Proteins/immunology , Recombinant Proteins/pharmacology , SARS-CoV-2/immunology , Severity of Illness Index
Int J Mol Sci ; 22(4)2021 Feb 12.
Article in English | MEDLINE | ID: covidwho-1085074


One of the most severe effects of coronavirus disease 2019 (COVID-19) is lung disorders such as acute respiratory distress syndrome. In the absence of effective treatments, it is necessary to search for new therapies and therapeutic targets. Platelets play a fundamental role in respiratory disorders resulting from viral infections, being the first line of defense against viruses and essential in maintaining lung function. The direct application of platelet lysate (PL) obtained from the platelet-rich plasma of healthy donors could help in the improvement of the patient due its anti-inflammatory, immunomodulatory, antifibrotic, and repairing effects. This work evaluates PL nebulization by analyzing its levels of growth factors and its biological activity on lung fibroblast cell cultures, besides describing a scientific basis for its use in this kind of pathology. The data of the work suggest that the molecular levels and biological activity of the PL are maintained after nebulization. Airway administration would allow acting directly on the lung tissue modulating inflammation and stimulating reparative processes on key structures such as the alveolocapillary barrier, improving the disease and sequels. The protocol developed in this work is a first step for the study of nebulized PL both in animal experimentation and in clinical trials.

Anti-Inflammatory Agents/pharmacology , COVID-19/therapy , Immunologic Factors/pharmacology , Intercellular Signaling Peptides and Proteins/pharmacology , Platelet-Rich Plasma , Adult , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/immunology , Blood Platelets/immunology , COVID-19/immunology , Cell Line , Female , Humans , Immunologic Factors/administration & dosage , Immunologic Factors/immunology , Intercellular Signaling Peptides and Proteins/administration & dosage , Intercellular Signaling Peptides and Proteins/immunology , Male , Nebulizers and Vaporizers , Platelet-Rich Plasma/immunology , SARS-CoV-2/immunology , Treatment Outcome
Signal Transduct Target Ther ; 5(1): 100, 2020 06 19.
Article in English | MEDLINE | ID: covidwho-606785